Clinical trials · Washington, D.C., DC
Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials in Washington, D.C.
We’re tracking 30 recruiting pancreatic ductal adenocarcinoma (pdac) studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Fairfax, VirginiaAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Fairfax, VirginiaAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Study of spevatamig for advanced gastrointestinal cancers
This trial tests a new drug called spevatamig (PT886) alone or with other treatments for advanced stomach, gastric, pancreatic, bile duct, or colorectal cancers. The goal is to see if it helps slow or stop cancer growth.
Fairfax, VirginiaAges 18 years+ - NCT07812805RecruitingPhase 1
New targeted treatment with imaging for advanced solid tumors
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Glen Burnie, MarylandAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Baltimore, MarylandAges 18 years+ - NCT07621718RecruitingPhase 3
Zoldonrasib plus chemotherapy for metastatic pancreatic cancer with KRAS mutation
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
Baltimore, MarylandAges 18 years+
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Pancreatic Ductal Adenocarcinoma (PDAC) trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting pancreatic ductal adenocarcinoma (pdac) studies listed above.
- Dren Investigational Site
- Johns Hopkins University
- NEXT Oncology
- Sidney Kimmel Comprehensive Cancer at Johns Hopkins
- The Sidney Kimmel Comprehensive Cancer Center at John Hopkins
- United Theranostics
- Virginia Cancer Specialists
What taking part in a pancreatic ductal adenocarcinoma (pdac) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there pancreatic ductal adenocarcinoma (pdac) clinical trials near Washington, D.C.?
- Yes. We're currently tracking 30 recruiting pancreatic ductal adenocarcinoma (pdac) studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a pancreatic ductal adenocarcinoma (pdac) study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a pancreatic ductal adenocarcinoma (pdac) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New pancreatic ductal adenocarcinoma (pdac) studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.